Dynavax Pops With CDC Recommendation

Health and Healthcare

Published: February 21, 2018 11:30 am

Last Updated: January 12, 2020 3:12 am

Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain early on Wednesday after the company announced that it received a recommendation from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Essentially the ACIP voted unanimously in favor of including Heplisav-B on its list of recommended products for use to vaccinate adults against hepatitis B. Heplisav-B was approved by the U.S. Food and Drug Administration (FDA) in November 2017 for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Ultimately, the receipt of the ACIP recommendation is a key step in providing patients with broad access to Heplisav-B. Medical policies of many insurance plans and institutions require ACIP recommendation before a vaccine is covered or available to their patients.

Dynavax commercially launched Heplisav-B in the United States in January 2018, and it announced Tuesday that the field sales team will begin actively selling Heplisav-B next week.

Eddie Gray, CEO of Dynavax, commented:

With the ACIP’s recommendation, HEPLISAV-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial goals. Additionally, this recognition emphasizes the important role of HEPLISAV-B in the prevention of hepatitis B infection in adults, reinforcing our belief that our unique two-dose vaccine with demonstrated higher rates of protection versus ENGERIX-B, and a safety profile similar to three-dose vaccines, will become the new standard of care for adults.

Shares of Dynavax were last seen up about 2% at $17.65 on Wednesday, with a consensus analyst price target of $29.00 and a 52-week range of $3.90 to $24.45.

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.